齐拉西酮与利培酮治疗精神分裂症的效果及安全性比较  

Comparison of efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia

作　　者：马军旗 张剑 师宁[2] MA Jun-qi;ZHANG Jian;SHI Ning(Mental Health Center of Yulin City, Yulin 719000;Affiliated Hospital of Yan'an University, Yan'an 716000, China)

机构地区：[1]榆林市精神卫生中心,陕西榆林719000 [2]延安大学附属医院,陕西延安716000

出　　处：《临床医学研究与实践》2019年第10期9-11,共3页Clinical Research and Practice

基　　金：延安市科学技术研究发展计划项目(No.2016KS-03)

摘　　要：目的探讨齐拉西酮与利培酮治疗精神分裂症的效果及安全性。方法将我院收治的精神分裂症患者156例根据治疗方法不同分为观察组和对照组,各78例。观察组给予齐拉西酮治疗,对照组给予利培酮治疗,两组患者均治疗2年。比较两组治疗前、后的阳性与阴性症状量表(PANSS)评分、临床疗效总评定量表(CGI)评分及不良反应发生情况。结果两组患者治疗2周、12周、6个月、1年、2年的PANSS总分、SI评分均明显低于治疗前(P<0.05);两组患者治疗12周、6个月、1年、2年的GI评分均明显低于治疗2周(P<0.05);两组患者各时间点PANSS总分、GI评分、SI评分比较,差异无统计学意义(P>0.05)。与观察组比较,对照组患者肌强直、震颤、静坐不能、体质量增加及月经改变或泌乳的发生率明显更高(P<0.05)。结论齐拉西酮应用于精神分裂症患者维持治疗可获得与利培酮相当的临床效果,两者均可明显改善临床症状,但应用齐拉西酮的不良反应发生率相对较低,安全性较高。Objective To investigate the efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia. Methods A total of 156 schizophrenic patients treated in our hospital were divided into observation group and control group according to different treatment methods, with 78 cases in each group. The observation group and control group were treated with ziprasidone and risperidone respectively, and both groups were treated for 2 years. The positive and negative symptoms scale (PANSS), clinical global impression (CGI) before and after treatment and adverse reactions were compared between the two groups. Results The total score of PANSS and SI scores of the two groups at 2 weeks, 12 weeks, 6 months, 1 year and 2 years of treatment were significantly lower than those before treatment (P<0.05). The GI scores at 12 weeks, 6 months, 1 year and 2 years of treatment in both groups were significantly lower than those at 2 weeks of treatment (P<0.05). There were no significant differences in PANSS total score, GI score and SI score in each time point between the two groups (P>0.05). Compared with the observation group, the incidences of myotonia, tremor, sedentary inability, increased body mass, menstrual changes or lactation in the control group were significantly higher (P<0.05). Conclusion Ziprasidone and risperidone can achieve the same clinical effect in the maintenance treatment of schizophrenia patients. Both of them can significantly improve the clinical symptoms of patients, but the incidence of adverse reactions of patients treated with ziprasidone is relatively low, with higher safety.

关 键 词：精神分裂症 齐拉西酮 利培酮 

分 类 号：R749.3[医药卫生—神经病学与精神病学]